{"id":10489,"date":"2018-01-26T09:56:56","date_gmt":"2018-01-26T14:56:56","guid":{"rendered":"https:\/\/research.ncsu.edu\/otcnv\/?p=10489"},"modified":"2023-01-26T23:22:15","modified_gmt":"2023-01-26T23:22:15","slug":"nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment","status":"publish","type":"post","link":"https:\/\/research.ncsu.edu\/commercialization\/2018\/01\/26\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\/","title":{"rendered":"NC&#160;State Startup Biomarck Pharmaceuticals launches Phase 2 clinical trial for lung cancer treatment"},"content":{"rendered":"\n<p>Durham-based&nbsp;<a href=\"http:\/\/www.biomarck.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">Biomarck Pharmaceuticals<\/a>, a portfolio company of the North Carolina Biotechnology Center, has launched a Phase 2 clinical trial of a potential therapy for treating advanced non-small cell lung cancer (NSCLC).<\/p>\n\n\n\n<p>The study at 10 sites in India will evaluate the safety and efficacy of Biomarck\u2019s novel, patented protein inhibitor, a peptide denoted as BIO-11006, the company said in a news release. The study will compare standard of care therapy \u2014 a combination of the chemotherapy drugs pemetrexed and carboplatin \u2014 to standard of care plus BIO-11006.<\/p>\n\n\n<div class=\"wp-block-ncst-buttons\"><div class=\"wp-block-ncst-button\"><a href=\"https:\/\/www.wraltechwire.com\/2018\/01\/25\/durhams-biomarck-pharmaceuticals-lanes-phase-2-clinical-trial-for-lung-cancer-treatment\/\" class=\"btn ncst-component__button-link\" data-ncst-lightbox=\"false\" data-ua-cat=\"Button Block\" data-ua-action=\"Button Click\" data-ua-label=\"https:\/\/www.wraltechwire.com\/2018\/01\/25\/durhams-biomarck-pharmaceuticals-lanes-phase-2-clinical-trial-for-lung-cancer-treatment\/\"><span class=\"ncst-component__button-container\"><span>Read <\/span><span class=\"nowrap\"><span>More&nbsp;<\/span><span class=\"arrow-indicator\"> <svg class=\"wolficon\" role=\"img\" aria-hidden=\"true\"><use xlink:href=\"#wolficon-arrow-right-bold\"\/><\/svg> <\/span><\/span><\/span><\/a><\/div>\n\n<\/div>\n\n","protected":false,"raw":"<!-- wp:ncst\/dynamic-header -->\n<!-- wp:ncst\/default-post-header \/-->\n<!-- \/wp:ncst\/dynamic-header -->\n\n<!-- wp:paragraph -->\n<p>Durham-based&nbsp;<a href=\"http:\/\/www.biomarck.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">Biomarck Pharmaceuticals<\/a>, a portfolio company of the North Carolina Biotechnology Center, has launched a Phase 2 clinical trial of a potential therapy for treating advanced non-small cell lung cancer (NSCLC).<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>The study at 10 sites in India will evaluate the safety and efficacy of Biomarck\u2019s novel, patented protein inhibitor, a peptide denoted as BIO-11006, the company said in a news release. The study will compare standard of care therapy \u2014 a combination of the chemotherapy drugs pemetrexed and carboplatin \u2014 to standard of care plus BIO-11006.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:ncst\/buttons -->\n<div class=\"wp-block-ncst-buttons\"><!-- wp:ncst\/button {\"text\":\"Read More\"} -->\n<div class=\"wp-block-ncst-button\"><a href=\"https:\/\/www.wraltechwire.com\/2018\/01\/25\/durhams-biomarck-pharmaceuticals-lanes-phase-2-clinical-trial-for-lung-cancer-treatment\/\" class=\"btn ncst-component__button-link\" data-ncst-lightbox=\"false\" data-ua-cat=\"Button Block\" data-ua-action=\"Button Click\" data-ua-label=\"https:\/\/www.wraltechwire.com\/2018\/01\/25\/durhams-biomarck-pharmaceuticals-lanes-phase-2-clinical-trial-for-lung-cancer-treatment\/\"><span class=\"ncst-component__button-container\"><span>Read <\/span><span class=\"nowrap\"><span>More&nbsp;<\/span><span class=\"arrow-indicator\"> <svg class=\"wolficon\" role=\"img\" aria-hidden=\"true\"><use xlink:href=\"#wolficon-arrow-right-bold\"\/><\/svg> <\/span><\/span><\/span><\/a><\/div>\n<!-- \/wp:ncst\/button --><\/div>\n<!-- \/wp:ncst\/buttons -->"},"excerpt":{"rendered":"<p>Durham-based&nbsp;Biomarck Pharmaceuticals, a portfolio company of the North Carolina Biotechnology Center, has launched a Phase 2 clinical trial of a potential therapy for treating advanced non-small cell lung cancer (NSCLC).&hellip;<\/p>\n","protected":false},"author":239,"featured_media":12304,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"source":"","ncst_custom_author":"","ncst_show_custom_author":false,"ncst_dynamicHeaderBlockName":"ncst\/default-post-header","ncst_dynamicHeaderData":"{\"showAuthor\":false,\"showDate\":true,\"showFeaturedVideo\":false,\"caption\":\"\"}","ncst_content_audit_freq":"","ncst_content_audit_date":"","ncst_content_audit_display":false,"ncst_backToTopFlag":"","footnotes":""},"categories":[2,3],"tags":[31,52,123,161,162],"_ncst_magazine_issue":[],"class_list":["post-10489","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-startup-news","tag-biomarck","tag-clinical-trial","tag-lung-cancer","tag-pharmaceuticals","tag-phase-2"],"displayCategory":null,"acf":{"ncst_posts_meta_modified_date":null},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NC State Startup Biomarck Pharmaceuticals launches Phase 2 clinical trial for lung cancer treatment - Office of Research Commercialization<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/research.ncsu.edu\/commercialization\/2018\/01\/26\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NC State Startup Biomarck Pharmaceuticals launches Phase 2 clinical trial for lung cancer treatment - Office of Research Commercialization\" \/>\n<meta property=\"og:description\" content=\"Durham-based&nbsp;Biomarck Pharmaceuticals, a portfolio company of the North Carolina Biotechnology Center, has launched a Phase 2 clinical trial of a potential therapy for treating advanced non-small cell lung cancer (NSCLC).&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/research.ncsu.edu\/commercialization\/2018\/01\/26\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Office of Research Commercialization\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-26T14:56:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-01-26T23:22:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sasha Campbell\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sasha Campbell\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2018\\\/01\\\/26\\\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2018\\\/01\\\/26\\\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\\\/\"},\"author\":{\"name\":\"Sasha Campbell\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#\\\/schema\\\/person\\\/2df2b886ab8c62292fb07ec4b03d51e8\"},\"headline\":\"NC&#160;State Startup Biomarck Pharmaceuticals launches Phase 2 clinical trial for lung cancer treatment\",\"datePublished\":\"2018-01-26T14:56:56+00:00\",\"dateModified\":\"2023-01-26T23:22:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2018\\\/01\\\/26\\\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\\\/\"},\"wordCount\":101,\"image\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2018\\\/01\\\/26\\\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2018\\\/01\\\/Biomarck_Pharmaceuticals_logo.png\",\"keywords\":[\"Biomarck\",\"clinical trial\",\"lung cancer\",\"pharmaceuticals\",\"Phase 2\"],\"articleSection\":[\"News\",\"Startup News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2018\\\/01\\\/26\\\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\\\/\",\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2018\\\/01\\\/26\\\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\\\/\",\"name\":\"NC State Startup Biomarck Pharmaceuticals launches Phase 2 clinical trial for lung cancer treatment - Office of Research Commercialization\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2018\\\/01\\\/26\\\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2018\\\/01\\\/26\\\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2018\\\/01\\\/Biomarck_Pharmaceuticals_logo.png\",\"datePublished\":\"2018-01-26T14:56:56+00:00\",\"dateModified\":\"2023-01-26T23:22:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#\\\/schema\\\/person\\\/2df2b886ab8c62292fb07ec4b03d51e8\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2018\\\/01\\\/26\\\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2018\\\/01\\\/26\\\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2018\\\/01\\\/26\\\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2018\\\/01\\\/Biomarck_Pharmaceuticals_logo.png\",\"contentUrl\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2018\\\/01\\\/Biomarck_Pharmaceuticals_logo.png\",\"width\":300,\"height\":300,\"caption\":\"startup company logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2018\\\/01\\\/26\\\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NC&#160;State Startup Biomarck Pharmaceuticals launches Phase 2 clinical trial for lung cancer treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#website\",\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/\",\"name\":\"Office of Research Commercialization\",\"description\":\"Just another Research and Innovation site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#\\\/schema\\\/person\\\/2df2b886ab8c62292fb07ec4b03d51e8\",\"name\":\"Sasha Campbell\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g\",\"caption\":\"Sasha Campbell\"},\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/author\\\/sasha-campbell\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NC State Startup Biomarck Pharmaceuticals launches Phase 2 clinical trial for lung cancer treatment - Office of Research Commercialization","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/research.ncsu.edu\/commercialization\/2018\/01\/26\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\/","og_locale":"en_US","og_type":"article","og_title":"NC State Startup Biomarck Pharmaceuticals launches Phase 2 clinical trial for lung cancer treatment - Office of Research Commercialization","og_description":"Durham-based&nbsp;Biomarck Pharmaceuticals, a portfolio company of the North Carolina Biotechnology Center, has launched a Phase 2 clinical trial of a potential therapy for treating advanced non-small cell lung cancer (NSCLC).&hellip;","og_url":"https:\/\/research.ncsu.edu\/commercialization\/2018\/01\/26\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\/","og_site_name":"Office of Research Commercialization","article_published_time":"2018-01-26T14:56:56+00:00","article_modified_time":"2023-01-26T23:22:15+00:00","og_image":[{"width":300,"height":300,"url":"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png","type":"image\/png"}],"author":"Sasha Campbell","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Sasha Campbell"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/research.ncsu.edu\/commercialization\/2018\/01\/26\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\/#article","isPartOf":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2018\/01\/26\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\/"},"author":{"name":"Sasha Campbell","@id":"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8"},"headline":"NC&#160;State Startup Biomarck Pharmaceuticals launches Phase 2 clinical trial for lung cancer treatment","datePublished":"2018-01-26T14:56:56+00:00","dateModified":"2023-01-26T23:22:15+00:00","mainEntityOfPage":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2018\/01\/26\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\/"},"wordCount":101,"image":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2018\/01\/26\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png","keywords":["Biomarck","clinical trial","lung cancer","pharmaceuticals","Phase 2"],"articleSection":["News","Startup News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/research.ncsu.edu\/commercialization\/2018\/01\/26\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\/","url":"https:\/\/research.ncsu.edu\/commercialization\/2018\/01\/26\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\/","name":"NC State Startup Biomarck Pharmaceuticals launches Phase 2 clinical trial for lung cancer treatment - Office of Research Commercialization","isPartOf":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/#website"},"primaryImageOfPage":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2018\/01\/26\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\/#primaryimage"},"image":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2018\/01\/26\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png","datePublished":"2018-01-26T14:56:56+00:00","dateModified":"2023-01-26T23:22:15+00:00","author":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8"},"breadcrumb":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2018\/01\/26\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/research.ncsu.edu\/commercialization\/2018\/01\/26\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/research.ncsu.edu\/commercialization\/2018\/01\/26\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\/#primaryimage","url":"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png","contentUrl":"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png","width":300,"height":300,"caption":"startup company logo"},{"@type":"BreadcrumbList","@id":"https:\/\/research.ncsu.edu\/commercialization\/2018\/01\/26\/nc-state-startup-biomarck-pharmaceuticals-launches-phase-2-clinical-trial-for-lung-cancer-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/research.ncsu.edu\/commercialization\/"},{"@type":"ListItem","position":2,"name":"NC&#160;State Startup Biomarck Pharmaceuticals launches Phase 2 clinical trial for lung cancer treatment"}]},{"@type":"WebSite","@id":"https:\/\/research.ncsu.edu\/commercialization\/#website","url":"https:\/\/research.ncsu.edu\/commercialization\/","name":"Office of Research Commercialization","description":"Just another Research and Innovation site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/research.ncsu.edu\/commercialization\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8","name":"Sasha Campbell","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g","caption":"Sasha Campbell"},"url":"https:\/\/research.ncsu.edu\/commercialization\/author\/sasha-campbell\/"}]}},"_links":{"self":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts\/10489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/users\/239"}],"replies":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/comments?post=10489"}],"version-history":[{"count":1,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts\/10489\/revisions"}],"predecessor-version":[{"id":14436,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts\/10489\/revisions\/14436"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/media\/12304"}],"wp:attachment":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/media?parent=10489"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/categories?post=10489"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/tags?post=10489"},{"taxonomy":"_ncst_magazine_issue","embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/_ncst_magazine_issue?post=10489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}